Subclinical Cardiovascular Disease in Psoriatic Disease
Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
This study will look at how chronic inflammation seen in psoriatic disease translates into
the increased atherosclerotic and thrombotic risk and how treatment reduces this CVD risk.
The Aim of this study is to 1) Evaluate the association between moderate to severe psoriatic
disease and measures of vascular function. 2) Evaluate the association between moderate to
severe psoriatic disease and measures of thrombotic risk. 3) Understand how traditional
medications used in cardiovascular disease (CVD) prevention such as aspirin and statins
affect vascular function and thrombotic risk in those with moderate to severe psoriatic
disease.
Phase:
Phase 4
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health